G
Gregor Winkels
Researcher at Miltenyi Biotec
Publications - 11
Citations - 2339
Gregor Winkels is an academic researcher from Miltenyi Biotec. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 9, co-authored 11 publications receiving 2168 citations.
Papers
More filters
Journal ArticleDOI
BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction
Andrzej Dzionek,Yoshiaki Sohma,Jun Nagafune,Marina Cella,Marco Colonna,Fabio Facchetti,Gritt Günther,C. Ian Johnston,Antonio Lanzavecchia,Tomoko Nagasaka,Tsutomu Okada,William Vermi,Gregor Winkels,Terumi Yamamoto,Monika Zysk,Yasunori Yamaguchi,Jürgen Schmitz +16 more
TL;DR: Triggering of BDCA-2 should be evaluated as therapeutic strategy for blocking production of interferon alpha/beta in systemic lupus erythematosus patients.
Journal ArticleDOI
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF
Luigi Dolcetti,Elisa Peranzoni,Stefano Ugel,Ilaria Marigo,Audry Fernandez Gomez,Circe Mesa,Markus Geilich,Gregor Winkels,Elisabetta Traggiai,Anna Casati,Fabio Grassi,Vincenzo Bronte +11 more
TL;DR: In vitro assays unveil a hierarchy of immunoregulatory activity among MDSC subsets that is controlled by tumor‐released GM‐CSF, and Gene silencing experiments indicated that GM‐ CSF was necessary to induce preferential expansion of both CD11b+/Gr‐1int and CD11B+/ Gr‐1low subsets in the spleen of tumor‐bearing mice and mediate tumor‐induced tolerance.
Journal ArticleDOI
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
Jurjen Tel,Erik H.J.G. Aarntzen,Tetsuro Baba,Gerty Schreibelt,Barbara M. Schulte,Daniel Benitez-Ribas,Otto C. Boerman,Sandra Croockewit,Wim J.G. Oyen,Michelle M. van Rossum,Gregor Winkels,Pierre Coulie,Cornelis J. A. Punt,Carl G. Figdor,I. Jolanda M. de Vries +14 more
TL;DR: The results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses.
Journal ArticleDOI
Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions.
Andrzej Dzionek,Yoshimasa Inagaki,Katsuya Okawa,Jun Nagafune,J.ürgen Röck,Yoshiaki Sohma,Gregor Winkels,Monika Zysk,Yasunori Yamaguchi,J.ürgen Schmitz +9 more
TL;DR: A panel of monoclonal antibodies, that recognize two novel leukocyte surface antigens,BDCA-2 and BDCA-4, are described, which may play a role in switching from interferon (IFN)-alpha/beta-controlled to interleukin (IL)-12-controlled immune response pathways.
Journal ArticleDOI
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Gerty Schreibelt,Kalijn F. Bol,Harm Westdorp,Florian Wimmers,Erik H.J.G. Aarntzen,Tjitske Duiveman-de Boer,Mandy W.M.M. van de Rakt,Nicole M. Scharenborg,Annemiek J. de Boer,Jeanette M. Pots,Michel A.M. Olde Nordkamp,Tom G. M. van Oorschot,Jurjen Tel,Gregor Winkels,Katja Petry,Willeke A. M. Blokx,Michelle M. van Rossum,Marieke E. B. Welzen,Roel Mus,Sandra Croockewit,Rutger H. T. Koornstra,Joannes F M Jacobs,Sander Kelderman,Christian U. Blank,Winald R. Gerritsen,Cornelis J. A. Punt,Carl G. Figdor,I. Jolanda M. de Vries +27 more
TL;DR: It is shown that vaccination of metastatic melanoma patients with primary myeloid DCs is feasible and safe and results in induction of effective antitumor immune responses that coincide with improved progression-free survival.